Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD.
Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for COPD. Yupelri’s mechanism of action involves inhibiting M3 receptors in the smooth muscle, leading to bronchodilation.
A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient.
This milestone triggers a one-time payment of $7.5 million from Viatris to Theravance Biopharma Inc. (NASDAQ:TBPH), which is expected in Q3 2025. Theravance Biopharma is also eligible to receive up to an additional $37.5 million in sales-related milestones and escalating royalties ranging from 14% to 20% on net sales of Yupelri in China.
Viatris Inc. (NASDAQ:VTRS) is a healthcare company that operates in 4 segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Theravance Biopharma Inc. (NASDAQ:TBPH) is a biopharmaceutical company that develops and commercializes medicines in the US.
While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
